AstronauTx builds executive team with appointment of experienced clinical development leader Michelle Mellion, MD as Chief Medical Officer
- Brings more than 20 years of neurology, clinical development, and translational experience as AstronauTx prepares to advance its lead programmes into clinical development
- AstronauTx also appoints Deb Gouveia as Vice President, Clinical Operations and Development Strategy to further strengthen clinical development capabilities
London, UK, 12 May 2026 – AstronauTx Ltd (“AstronauTx”), a biotechnology company developing therapeutics to treat Alzheimer’s Disease and other neurological disorders by improving sleep architecture, announces the appointments of Dr. Michelle Mellion as Chief Medical Officer (CMO) and Deb Gouveia as Vice President, Clinical Operations and Development Strategy.
